210 related articles for article (PubMed ID: 16253950)
21. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model.
Chow TH; Lin YY; Hwang JJ; Wang HE; Tseng YL; Wang SJ; Liu RS; Lin WJ; Yang CS; Ting G
Anticancer Res; 2009 Jun; 29(6):2111-20. PubMed ID: 19528471
[TBL] [Abstract][Full Text] [Related]
22. Comparative study of the in vitro and in vivo characteristics of cationic and neutral liposomes.
Zhao W; Zhuang S; Qi XR
Int J Nanomedicine; 2011; 6():3087-98. PubMed ID: 22163162
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic Acid.
Semple SC; Harasym TO; Clow KA; Ansell SM; Klimuk SK; Hope MJ
J Pharmacol Exp Ther; 2005 Mar; 312(3):1020-6. PubMed ID: 15525796
[TBL] [Abstract][Full Text] [Related]
24. Polyethylene glycol (PEG) modified 99mTc-HMPAO-liposome for improving blood circulation and biodistribution: the effect of the extent of PEGylation.
Lee CM; Choi Y; Huh EJ; Lee KY; Song HC; Sun MJ; Jeong HJ; Cho CS; Bom HS
Cancer Biother Radiopharm; 2005 Dec; 20(6):620-8. PubMed ID: 16398614
[TBL] [Abstract][Full Text] [Related]
25. Surface functionalized cationic lipid-DNA complexes for gene delivery: PEGylated lamellar complexes exhibit distinct DNA-DNA interaction regimes.
Martin-Herranz A; Ahmad A; Evans HM; Ewert K; Schulze U; Safinya CR
Biophys J; 2004 Feb; 86(2):1160-8. PubMed ID: 14747350
[TBL] [Abstract][Full Text] [Related]
26. Characterization of cationic liposome formulations designed to exhibit extended plasma residence times and tumor vasculature targeting properties.
Ho EA; Ramsay E; Ginj M; Anantha M; Bregman I; Sy J; Woo J; Osooly-Talesh M; Yapp DT; Bally MB
J Pharm Sci; 2010 Jun; 99(6):2839-53. PubMed ID: 20091826
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of dipalmitoylphosphatidylcholine liposomes containing a soybean-derived sterylglucoside mixture for liver targeting.
Shimizu K; Maitani Y; Takayama K; Nagai T
J Drug Target; 1996; 4(4):245-53. PubMed ID: 9010814
[TBL] [Abstract][Full Text] [Related]
28. Nanostructure of polyplexes formed between cationic diblock copolymer and antisense oligodeoxynucleotide and its influence on cell transfection efficiency.
Zhao X; Pan F; Zhang Z; Grant C; Ma Y; Armes SP; Tang Y; Lewis AL; Waigh T; Lu JR
Biomacromolecules; 2007 Nov; 8(11):3493-502. PubMed ID: 17939715
[TBL] [Abstract][Full Text] [Related]
29. Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol.
Wang S; Lee RJ; Cauchon G; Gorenstein DG; Low PS
Proc Natl Acad Sci U S A; 1995 Apr; 92(8):3318-22. PubMed ID: 7724560
[TBL] [Abstract][Full Text] [Related]
30. Enhanced siRNA delivery using cationic liposomes with new polyarginine-conjugated PEG-lipid.
Kim HK; Davaa E; Myung CS; Park JS
Int J Pharm; 2010 Jun; 392(1-2):141-7. PubMed ID: 20347025
[TBL] [Abstract][Full Text] [Related]
31. [Cationic lipid and polyethylene glycol enhance liposomes-mediated cell transfection and increase the fluidity of liposomes membranes].
Yan WW; Qi XR; Wei L; Fei R; Cong X; Wang Y
Yao Xue Xue Bao; 2003 Sep; 38(9):698-701. PubMed ID: 14730922
[TBL] [Abstract][Full Text] [Related]
32. Intracellular delivery of poly(ethylene glycol) conjugated antisense oligonucleotide using cationic lipids by formation of self-assembled polyelectrolyte complex micelles.
Jeong JH; Kim SH; Kim SW; Park TG
J Nanosci Nanotechnol; 2006; 6(9-10):2790-5. PubMed ID: 17048484
[TBL] [Abstract][Full Text] [Related]
33. A novel, long-circulating, and functional liposomal formulation of antisense oligodeoxynucleotides targeted against MDR1.
Stuart DD; Kao GY; Allen TM
Cancer Gene Ther; 2000 Mar; 7(3):466-75. PubMed ID: 10766353
[TBL] [Abstract][Full Text] [Related]
34. Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo.
Leamon CP; Cooper SR; Hardee GE
Bioconjug Chem; 2003; 14(4):738-47. PubMed ID: 12862426
[TBL] [Abstract][Full Text] [Related]
35. Efficient delivery of an antisense oligodeoxyribonucleotide formulated in folate receptor-targeted liposomes.
Chiu SJ; Marcucci G; Lee RJ
Anticancer Res; 2006; 26(2A):1049-56. PubMed ID: 16619505
[TBL] [Abstract][Full Text] [Related]
36. [Preparation and in vitro and in vivo study of antisense oligodeoxynucleotides-loaded cationic liposomes].
Liu Y; Zhang ZZ; Li K; Mei Q
Yao Xue Xue Bao; 2009 Nov; 44(11):1273-7. PubMed ID: 21355327
[TBL] [Abstract][Full Text] [Related]
37. [Preparation and properties of folate receptor-targeted cationic liposomes].
Yan Y; Qi XR
Yao Xue Xue Bao; 2008 Nov; 43(11):1134-9. PubMed ID: 19239034
[TBL] [Abstract][Full Text] [Related]
38. PEG-appended beta-(1-->3)-D-glucan schizophyllan to deliver antisense-oligonucleotides with avoiding lysosomal degradation.
Karinaga R; Koumoto K; Mizu M; Anada T; Shinkai S; Sakurai K
Biomaterials; 2005 Aug; 26(23):4866-73. PubMed ID: 15763266
[TBL] [Abstract][Full Text] [Related]
39. Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures.
Semple SC; Klimuk SK; Harasym TO; Dos Santos N; Ansell SM; Wong KF; Maurer N; Stark H; Cullis PR; Hope MJ; Scherrer P
Biochim Biophys Acta; 2001 Feb; 1510(1-2):152-66. PubMed ID: 11342155
[TBL] [Abstract][Full Text] [Related]
40. Development of glycyrrhetinic acid-modified stealth cationic liposomes for gene delivery.
He ZY; Zheng X; Wu XH; Song XR; He G; Wu WF; Yu S; Mao SJ; Wei YQ
Int J Pharm; 2010 Sep; 397(1-2):147-54. PubMed ID: 20667672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
